These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22134010)

  • 1. Gabapentin: a novel drug as add-on therapy in cases of refractory overactive bladder in children.
    Ansari MS; Bharti A; Kumar R; Ranjan P; Srivastava A; Kapoor R
    J Pediatr Urol; 2013 Feb; 9(1):17-22. PubMed ID: 22134010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gabapentin treatment of neurogenic overactive bladder.
    Carbone A; Palleschi G; Conte A; Bova G; Iacovelli E; Bettolo CM; Pastore A; Inghilleri M
    Clin Neuropharmacol; 2006; 29(4):206-14. PubMed ID: 16855422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
    Chua ME; See MC; Esmeňa EB; Balingit JC; Morales ML
    Low Urin Tract Symptoms; 2018 May; 10(2):135-142. PubMed ID: 28150436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study.
    Schulte-Baukloh H; Mürtz G; Heine G; Austin P; Miller K; Michael T; Strugala G; Knispel HH
    J Pediatr Urol; 2012 Aug; 8(4):386-92. PubMed ID: 21907623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
    Bach P; Wormland RT; Möhring C; Goepel M
    Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
    Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
    J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
    Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
    Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double anticholinergic therapy for refractory overactive bladder.
    Bolduc S; Moore K; Lebel S; Lamontagne P; Hamel M
    J Urol; 2009 Oct; 182(4 Suppl):2033-8. PubMed ID: 19695628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective open label study of solifenacin for overactive bladder in children.
    Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
    J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.
    Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E
    Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
    Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S
    Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
    Grigoleit U; Mürtz G; Laschke S; Schuldt M; Goepel M; Kramer G; Stöhrer M
    Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the anticonvulsant medications pregabalin and lamotrigine on urodynamic parameters in an animal model of neurogenic detrusor overactivity.
    Loutochin O; Al Afraa T; Campeau L; Mahfouz W; Elzayat E; Corcos J
    Neurourol Urodyn; 2012 Sep; 31(7):1197-202. PubMed ID: 22473872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder.
    Neel KF; Soliman S; Salem M; Seida M; Al-Hazmi H; Khatab A
    J Urol; 2007 Dec; 178(6):2593-7; discussion 2597-8. PubMed ID: 17945300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of gabapentin and anticholinergics in management of neurogenic bladder after repair of spina bifida - a randomized controlled study.
    Dash V; Bawa M; Mahajan JK; Kanojia RP; Samujh R; Rao KL
    J Pediatr Surg; 2016 Dec; 51(12):2025-2029. PubMed ID: 27680597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The analgesic effect of gabapentin as a prophylactic anticonvulsant drug on postcraniotomy pain: a prospective randomized study.
    Türe H; Sayin M; Karlikaya G; Bingol CA; Aykac B; Türe U
    Anesth Analg; 2009 Nov; 109(5):1625-31. PubMed ID: 19713257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.